Founded in 2016 and headquartered in Hangzhou, CellGene Biotech Co., Ltd. is an in vitro diagnostics company focusing on the innovation and application of new immunodetection technologies and platforms. CellGene has the first "Cytokine Multiplex Detection Kit" approved by NMPA in China, the first NMPA II approved registration for Programmed Cell Death Protein 1(PD-1/ CD279) Detection Kit, Tumor-Associated Diagnostic Factor Multiplex Detection Kit, Soluble Inflammatory Factors Multiplex Detection Kit, Chemotactic Factor Multiplex Detection Kit, Immunoglobulin G Subclass Detection Kit, Alzheimer's Disease Multiplex Detection Kit, Absolute Count Beads kit, and over 200 types of flow cytometry complementary reagents.
Since establishment, CellGene has continuously achieved breakthroughs in its professional field, and garnered numerous honors such as the "High-Tech Enterprise Certification," "Top Ten Enterprise Growth Stars" and recognition as a "Specialized and New Small and Medium-sized Enterprise" in Jiangxi Province. It has been consecutively listed for three years in the "Potential Unicorn" rankings in Hangzhou. Focused on independent innovation, we aspire to become a globally influential leader in the field of clinical diagnostics, contributing to the well-being of humanity.
